US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
Open Access
- 1 June 2020
- journal article
- research article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 12, 317-325
Abstract
Objective: To estimate the budgetary impact of adopting selinexor (XPOVIO; Karyopharm Therapeutics, Inc.) for the treatment of adult patients with penta-refractory multiple myeloma (MM) from the perspective of a third-party payer in the United States (US). Methods: A budget impact analysis was conducted in one-year increments for the first 3 years after the introduction of selinexor for a private payer or Medicare Part D. Total annual treatment costs (2018 US dollars) were calculated as the sum of drug costs, costs of adverse events (AEs; grade ≥ 3), along with ongoing best supportive care costs. The number of eligible patients was derived from national epidemiology statistics, healthcare databases, and published literature. Results: In the base-case analysis, selinexor was associated with a per member per month (PMPM) cost of $0.0103 in year 3, assuming a market uptake of 64%, for a hypothetical private payer plan with one million members and four eligible patients. In a scenario analysis with 16 eligible patients with triple-class refractory MM regardless of the line of therapy (this additional scenario analysis was performed with an eligible population that does not fit squarely within the approved label for selinexor but was performed strictly for the purpose of demonstrating the results of the budget impact model when based on a larger pool of eligible patients), the estimated PMPM cost in year 3 was $0.0388. The model showed comparable sensitivity to treatment duration, wholesale acquisition cost for selinexor, and year 1 uptake. The base-case analysis conducted from the perspective of Medicare Part D was associated with a PMPM cost of $0.0078 in year 3 with 159 eligible patients. Conclusions: The model estimates a small and manageable budget impact of adopting selinexor into a third-party US payer plan, given the low prevalence of penta-refractory MM.Keywords
This publication has 29 references indexed in Scilit:
- Treatment Options for Triple-class Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2020
- Relapsed refractory multiple myeloma: a comprehensive overviewLeukemia, 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia, 2019
- Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody TherapyBlood, 2018
- Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective ofCD38 expression and is related to dismal prognosisEuropean Journal of Haematology, 2018
- Multiple myelomaNature Reviews Disease Primers, 2017
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyLeukemia, 2017
- How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?Critical Reviews in Oncology/Hematology, 2017
- Trends in overall survival and costs of multiple myeloma, 2000–2014Leukemia, 2016
- Current treatment landscape for relapsed and/or refractory multiple myelomaNature Reviews Clinical Oncology, 2014